Insmed (NASDAQ:INSM) Stock

INSMED INC

Insmed

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Insmed Inc

News

INSM

Reported Earlier, Insmed Prices $750M Public Offering Of 7,812,500 Shares At $96 Each

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) has outperformed the market over the past 10 years by 4.43% on an annualized basis producing an average annual return of 15.51%. Currently, Insmed has a market capitalization of $17.70 billion. 
Buying $100 In INSM: If an investor had bought $100 of INSM stock 10 years ago, it would be worth $425.63 today based on a price of $97.20 for INSM at the time of writing.
<h3>Insmed's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749684615_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In Insmed 10 Years Ago Would Be Worth This Much Today

Offerings

Insmed Announces Proposed $650M Public Offering

Goldman Sachs analyst Andrea Tan maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and raises the price target from $100 to $112.

Price Target

Analyst Ratings

Goldman Sachs Maintains Buy on Insmed, Raises Price Target to $112

Insmed Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) on Tuesday released topline results from its Phase&nbsp;2b&nbsp;study of treprostinil palmitil inhalation powder (TPIP), administered once daily in patients with <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">pulmonary arterial hypertension</a>.
The study met its primary endpoint and all secondary efficacy endpoints. For the primary endpoint, the placebo-adjusted reduction from baseline in pulmonary vascular resistance (PVR) was 35%, with a Least Squares (LS)&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n45856129/insmed-announces-positive-topline-results-from-phase-2b-study-of-treprostinil-palmitil-inhalation-" rel="noreferrer noopener">mean ratio of 0.65</a>.
The placebo-adjusted improvement in six-minute walk distance (6MWD) was 35.5 meters for the secondary efficacy endpoints.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/02/43957368/lung-disease-focused-insmed-is-an-attractive-midcap-biotech-analyst-says" target="_blank" rel="noreferrer noopener">Lung Disease-Focused Insmed &#8216;Is An Attractive Midcap Biotech,&#8217; Analyst Says</a>
The placebo-adjusted reduction from baseline in N-terminal pro-b-type natriuretic peptide (NT-proBNP) concentrations, a biomarker for cardiac stress, was 60%, with an LS mean ratio of 0.40.
These results demonstrate the durability of TPIP&#8217;s therapeutic effect as a once-daily therapy based on efficacy evaluated approximately 24 hours after administering therapy.
Insmed will engage with the U.S. Food and Drug Administration (FDA) regarding the Phase 3 trial design for PAH.
Insmed plans to initiate a Phase 3 trial in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) before the end of 2025 and a Phase 3 trial in patients with PAH in early 2026.
Once-daily TPIP therapy was well tolerated in the study.
<h2 class="wp-block-heading">What Analysts Are Saying</h2>
Bank of America Securities (BofA) said TPIP data &#8216;exceeded even our bullish outlook.&#8217;
Analyst Jason Zemansky sees &#8220;clear potential for TPIP to become foundational in PAH/ PH-ILD, given the strength of the data and treprostinil&#8217;s well-established role in the paradigm.&#8221;
BofA analyst says that overall, the data looks strong, and there&#8217;s little to criticize. TPIP seems to have a top-tier profile, especially in how it&#8217;s administered. Plus, there&#8217;s good reason to think its effectiveness will improve with higher doses, and safety concerns may decrease with longer dose adjustments.
On Tuesday, BofA increased the price forecast from $94 to $109, <a href="https://www.benzinga.com/quote/INSM/analyst-ratings" target="_blank" rel="noreferrer noopener">reiterating its Buy rating</a>.
BofA still sees several short-term factors that could drive shares higher, but these aren&#8217;t fully reflected in the current price. One is the upcoming FDA decision on brensocatib, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43843781/insmed-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-business-update" rel="noreferrer noopener">expected by August 12</a>.
Although there are good reasons to be optimistic, investor skepticism remains around management&#8217;s ambitious goal of over $5 billion in peak sales. 
Meaningful insights into the launch likely won&#8217;t come until around the first quarter of 2026. However, early feedback from doctors and insurers in the second half of 2025 could help ease some doubts.
HC Wainwright maintained a Buy rating on Insmed and has raised the price forecast from $90 to $120.
Wells Fargo maintained an Overweight rating on Insmed and has raised the price forecast from $107 to $119.
Morgan Stanley maintained an Overweight rating on Insmed and has raised the price forecast from $90 to $102.
RBC Capital maintained an Outperform rating on Insmed and has raised the price forecast from $99 to $106.
Mizuho maintained an Outperform rating on Insmed and has raised the price forecast from $96 to $110.
Price Action: INSM stock is trading higher by 7.04% to $97.33 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45778064/newly-listed-sionna-therapeutics-touts-positive-data-from-lung-disease-candidate-in-healthy-volunteer-trial" target="_blank" rel="noreferrer noopener">Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Biotech

Large Cap

Health Care

Movers

General

Insmed's Pulmonary Hypertension Drug Data Exceeded Even Bullish Outlook, Analysts Boost Price Forecast

Mizuho analyst Graig Suvannavejh maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Outperform and raises the price target from $96 to $110.

Mizuho Maintains Outperform on Insmed, Raises Price Target to $110

RBC Capital analyst Leonid Timashev maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Outperform and raises the price target from $99 to $106.

RBC Capital Maintains Outperform on Insmed, Raises Price Target to $106

WIIM

Insmed shares are trading higher after the multiple firms raised their respective price targets on the stock.

Morgan Stanley analyst Matthew Harrison maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Overweight and raises the price target from $90 to $102.

Morgan Stanley Maintains Overweight on Insmed, Raises Price Target to $102

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Needham raised Lumentum Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) price target from $100 to $105. Needham analyst Ryan Koontz maintained a Buy rating. Lumentum shares closed at $81.96 on Tuesday. See how other analysts <a href="https://www.benzinga.com/quote/lite/analyst-ratings">view this stock</a>.</li>
<li>Telsey Advisory Group cut the price target for Academy Sports and Outdoors, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASO#NASDAQ">ASO</a>) from $60 to $58. Telsey Advisory Group analyst Cristina Fernandez maintained an Outperform rating. Academy Sports and Outdoors shares closed at $44.60 on Tuesday. See how other analysts view <a href="https://www.benzinga.com/quote/aso/analyst-ratings">this stock</a>.</li>
<li>HC Wainwright &amp; Co. raised Insmed Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) price target from $90 to $120. HC Wainwright &amp; Co. analyst Andrew Fein maintained a Buy rating. Insmed shares closed at $90.93 on Tuesday. <a href="https://www.benzinga.com/quote/insm/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Canaccord Genuity raised the price target for Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) from $87 to $99. Canaccord Genuity analyst Kyle Mikson maintained a Hold rating. Illumina shares closed at $87.98 on Tuesday. <a href="https://www.benzinga.com/quote/ilmn/analyst-ratings">See how other analysts view this stock.</a></li>
<li>BTIG slashed the price target for GitLab Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>) from $86 to $67. BTIG analyst Gary Powell maintained a Buy rating. GitLab shares closed at $48.51 on Tuesday. See how other analysts <a href="https://www.benzinga.com/quote/gtlb/analyst-ratings">view this stock</a>.</li>
<li>Benchmark raised TAT Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TATT#NASDAQ">TATT</a>) price target from $35 to $36. Benchmark analyst Josh Sullivan maintained a Buy rating. TAT Technologies shares settled at $26.40 on Tuesday. <a href="https://www.benzinga.com/quote/tatt/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo raised Marathon Petroleum Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>) price target from $180 to $182. Wells Fargo analyst Roger Read maintained an Overweight rating. Marathon Petroleum shares closed at $162.64 on Tuesday. <a href="https://www.benzinga.com/quote/mpc/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wells Fargo cut Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) price target from $149 to $147. Wells Fargo analyst Roger Read maintained an Overweight rating. Phillips 66 shares closed at $118.70 on Tuesday.  <a href="https://www.benzinga.com/quote/psx/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BTIG increased the price target for Super Group (SGHC) Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGHC#NYSE">SGHC</a>) from $9 to $11. BTIG analyst Clark Lampen maintained a Buy rating. Super Group shares settled at $9.30 on Tuesday. <a href="https://www.benzinga.com/quote/sghc/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS raised Datadog, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) price target from $125 to $140. UBS analyst Karl Keirstead maintained a Buy rating. Datadog shares closed at $119.91 on Tuesday. <a href="https://www.benzinga.com/quote/ddog/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying DDOG stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/DDOG/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="583" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/11091354/image-163-1024x583.png" alt="" class="wp-image-946172" style="width:622px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/11091354/image-163-1024x583.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/11091354/image-163-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/11091354/image-163-768x437.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/11091354/image-163.png 1112w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45858699/top-2-tech-and-telecom-stocks-you-may-want-to-dump-in-q2">Top 2 Tech And Telecom Stocks You May Want To Dump In Q2</a> </li>
</ul>
Photo via Shutterstock

Markets

DDOG

GTLB

ILMN

LITE

SGHC

TATT

Datadog To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday

B of A Securities analyst Jason Zemansky maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and raises the price target from $94 to $109.

B of A Securities Maintains Buy on Insmed, Raises Price Target to $109

Wells Fargo analyst Tiago Fauth maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Overweight and raises the price target from $107 to $119.

Wells Fargo Maintains Overweight on Insmed, Raises Price Target to $119

HC Wainwright &amp; Co. analyst Andrew Fein maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and raises the price target from $90 to $120.

HC Wainwright & Co. Maintains Buy on Insmed, Raises Price Target to $120

Throughout the last three months, 6 analysts have evaluated Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $102.5, with a high estimate of $115.00 and a low estimate of $90.00. Witnessing a positive shift, the current average has risen by 4.17% from the previous average price target of $98.40.
<img src="https://www.benzinga.com/files/images/story/2025/1749585648_0_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of Insmed's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Schwartz</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Kelly Shi</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$105.00</td>
<td>-</td>
</tr>
<tr>
<td>Trung Huynh</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$109.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Jason Zemansky</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$96.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Insmed. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Insmed compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Insmed's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/INSM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Insmed analyst ratings.</a>
<h2>Get to Know Insmed Better</h2>
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
<h3>A Deep Dive into Insmed's Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Insmed's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 22.94%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Insmed's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -276.42%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Insmed's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -133.45%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Insmed's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -13.41%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 11.53, caution is advised due to increased financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Insmed Stock: Analyst Perspectives (6 Ratings)

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 50 points n Tuesday.
The Dow traded up 0.13% to 42,817.81 while the NASDAQ gained 0.22% to 19,634.48. The S&amp;P 500 also rose, gaining, 0.29% to 6,023.46.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45858699/top-2-tech-and-telecom-stocks-you-may-want-to-dump-in-q2">Top 2 Tech And Telecom Stocks You May Want To Dump In Q2</a>
Leading and Lagging Sectors Energy shares jumped by 1.9% on Tuesday.
In trading on Tuesday, industrials stocks fell by 0.4%.
Top Headline
The NFIB Small Business Optimism Index rose to 98.8 in May from 95.8 in April and topping market estimates of 95.9.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Insmed Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) shares shot up 27% to $89.94 after the company announced topline results from its randomized, double-blind, placebo-controlled Phase 2b study evaluating the efficacy and safety of treprostinil palmitil inhalation powder met its primary endpoint and all secondary efficacy endpoints.</li>
<li>Shares of Casey&#8217;s General Stores, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASY#NASDAQ">CASY</a>) got a boost, surging 15% to $506.20 after the company reported better-than-expected fourth-quarter financial results and increased its quarterly dividend.</li>
<li>Evogene Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>) shares were also up, gaining 72% to $1.9399. Evogene announced completion of first-in-class foundation model for generative molecule design, developed in collaboration with Google Cloud.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Liquidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>) shares dropped 21% to $14.23 in reaction to Insmed&#8217;s drug to treat rare lung disease met its primary endpoint and all secondary efficacy endpoints.</li>
<li>Shares of Calavo Growers, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVGW#NASDAQ">CVGW</a>) were down 17% to $22.93 after the company reported worse-than-expected second-quarter financial results.</li>
<li>United Therapeutics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) was down, falling 16% to $276.38 in reaction to Insmed after its drug to treat rare lung disease met its primary endpoint and all secondary efficacy endpoints.</li>
</ul>
Commodities In commodity news, oil traded down 0.2% to $65.14 while gold traded down 0.3% at $3,344.80.
Silver traded down 0.6% to $36.570 on Tuesday, while copper fell 0.5% to $4.8990.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 rose 0.09%, while Spain's IBEX 35 Index rose 0.19%. London's FTSE 100 gained 0.45%, Germany's DAX 40 fell 0.35% and France's CAC 40 rose 0.09% during the session.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with Japan's Nikkei gaining 0.32%, Hong Kong's Hang Seng Index falling 0.08%, China's Shanghai Composite dipping 0.44% and India's BSE Sensex falling 0.07%.
Economics
The NFIB Small Business Optimism Index rose to 98.8 in May from 95.8 in April and topping market estimates of 95.9.
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45858699/top-2-tech-and-telecom-stocks-you-may-want-to-dump-in-q2">Top 2 Tech And Telecom Stocks You May Want To Dump In Q2</a> </li>
</ul>
Photo via Shutterstock

Earnings

Equities

Eurozone

Commodities

Intraday Update

CASY

CVGW

EVGN

LQDA

UTHR

Dow Gains 50 Points; US Small Business Optimism Index Rises In May

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/13/25</td>
<td>$55.00</td>
<td>$82.5K</td>
<td>2.3K</td>
<td>4.5K</td>
</tr>
<tr>
<td>LQDA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$15.00</td>
<td>$27.9K</td>
<td>723</td>
<td>1.1K</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/15/25</td>
<td>$27.50</td>
<td>$26.3K</td>
<td>3.6K</td>
<td>897</td>
</tr>
<tr>
<td>ALT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$6.00</td>
<td>$185.2K</td>
<td>930</td>
<td>783</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/19/25</td>
<td>$350.00</td>
<td>$80.9K</td>
<td>4.1K</td>
<td>712</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$115.00</td>
<td>$45.6K</td>
<td>2.5K</td>
<td>600</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$30.00</td>
<td>$27.2K</td>
<td>14.5K</td>
<td>195</td>
</tr>
<tr>
<td>INSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$75.00</td>
<td>$70.1K</td>
<td>420</td>
<td>157</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$75.00</td>
<td>$29.0K</td>
<td>1.6K</td>
<td>94</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$770.00</td>
<td>$32.4K</td>
<td>222</td>
<td>87</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option sweep with bearish sentiment. It expires in 3 day(s) on June 13, 2025. Parties traded 500 contract(s) at a $55.00 strike. This particular call needed to be split into 67 different trades to become filled. The total cost received by the writing party (or parties) was $82.5K, with a price of $165.0 per contract. There were 2313 open contracts at this strike prior to today, and today 4580 contract(s) were bought and sold. 
• Regarding LQDA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>), we observe a put option trade with neutral sentiment. It expires in 38 day(s) on July 18, 2025. Parties traded 215 contract(s) at a $15.00 strike. The total cost received by the writing party (or parties) was $27.9K, with a price of $130.0 per contract. There were 723 open contracts at this strike prior to today, and today 1174 contract(s) were bought and sold. 
• Regarding VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we observe a call option trade with neutral sentiment. It expires in 66 day(s) on August 15, 2025. Parties traded 40 contract(s) at a $27.50 strike. The total cost received by the writing party (or parties) was $26.3K, with a price of $659.0 per contract. There were 3634 open contracts at this strike prior to today, and today 897 contract(s) were bought and sold. 
• For ALT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>), we notice a put option sweep that happens to be bearish, expiring in 38 day(s) on July 18, 2025. This event was a transfer of 1122 contract(s) at a $6.00 strike. This particular put needed to be split into 62 different trades to become filled. The total cost received by the writing party (or parties) was $185.2K, with a price of $165.0 per contract. There were 930 open contracts at this strike prior to today, and today 783 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a call option trade that happens to be neutral, expiring in 192 day(s) on December 19, 2025. This event was a transfer of 40 contract(s) at a $350.00 strike. The total cost received by the writing party (or parties) was $80.9K, with a price of $2023.0 per contract. There were 4181 open contracts at this strike prior to today, and today 712 contract(s) were bought and sold. 
• For MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we notice a call option sweep that happens to be bearish, expiring in 220 day(s) on January 16, 2026. This event was a transfer of 600 contract(s) at a $115.00 strike. This particular call needed to be split into 49 different trades to become filled. The total cost received by the writing party (or parties) was $45.6K, with a price of $76.0 per contract. There were 2577 open contracts at this strike prior to today, and today 600 contract(s) were bought and sold. 
• For MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we notice a put option sweep that happens to be bullish, expiring in 101 day(s) on September 19, 2025. This event was a transfer of 50 contract(s) at a $30.00 strike. This particular put needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $27.2K, with a price of $545.0 per contract. There were 14560 open contracts at this strike prior to today, and today 195 contract(s) were bought and sold. 
• For INSM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>), we notice a call option sweep that happens to be bearish, expiring in 66 day(s) on August 15, 2025. This event was a transfer of 39 contract(s) at a $75.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $70.1K, with a price of $1806.0 per contract. There were 420 open contracts at this strike prior to today, and today 157 contract(s) were bought and sold. 
• Regarding NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we observe a call option trade with bullish sentiment. It expires in 220 day(s) on January 16, 2026. Parties traded 20 contract(s) at a $75.00 strike. The total cost received by the writing party (or parties) was $29.0K, with a price of $1450.0 per contract. There were 1606 open contracts at this strike prior to today, and today 94 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a put option sweep that happens to be bullish, expiring in 66 day(s) on August 15, 2025. This event was a transfer of 8 contract(s) at a $770.00 strike. This particular put needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $32.4K, with a price of $4055.0 per contract. There were 222 open contracts at this strike prior to today, and today 87 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

Hims & Hers Health, Inc. Class A Common Stock

HIMS

MRNA

VKTX

10 Health Care Stocks Whale Activity In Today's Session

U.S. stocks were mixed, with the Dow Jones index falling around 0.1% on Tuesday.
Shares of Insmed Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) rose sharply during Tuesday's session after the company announced topline results from its randomized, double-blind, placebo-controlled Phase 2b study evaluating the efficacy and safety of treprostinil palmitil inhalation powder met its primary endpoint and all <a href="https://www.benzinga.com/quote/INSM/analyst-ratings">secondary efficacy endpoints</a>.
Insmed Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) gained 27% to $89.78 on Tuesday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>NWTN Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) shares jumped 27.5% to $2.04.</li>
<li>Metsera, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSR#NASDAQ">MTSR</a>) gained 24% to $37.66.</li>
<li>Yatsen Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YSG#NYSE">YSG</a>) climbed 20.3% to $8.50.</li>
<li>Navitas Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) gained 19.4% to $8.08.</li>
<li>Plug Power Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) rose 16.8% to $1.4250 on what appears to be continued momentum following a more than 25% surge to start the week.</li>
<li>QuantaSing Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSG#NASDAQ">QSG</a>) jumped 14.5% to $7.96. Citigroup analyst Alice Cai upgraded QuantaSing Group from Neutral to Buy and raised the price target from $6.1 to $9.52.</li>
<li>Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) rose 14% to $16.39.</li>
<li>Casey&#8217;s General Stores, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASY#NASDAQ">CASY</a>) gained 13.8% to $500.07 after the company reported better-than-expected fourth-quarter financial results and increased its quarterly dividend.</li>
<li>Terns Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TERN#NASDAQ">TERN</a>) rose 12.4% to $4.1689.</li>
<li>Recursion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) gained 10.1% to $5.91 as the company announced a 20% workforce reduction and infrastructure streamlining to extend cash runway into Q4 2027.</li>
<li>Legend Biotech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>) rose 6.8% to $37.15.</li>
<li>Axcelis Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLS#NASDAQ">ACLS</a>) gained 6% to $71.68.</li>
<li>Cosan S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSAN#NYSE">CSAN</a>) rose 5.7% to $6.05.</li>
<li>Under Armour, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) gained 5% to $7.09.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rose 2.4% to $315.94. Tesla sold over 24,770 Model Ys in May in China, according to new insurance registration data obtained by Car News China on Monday.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/45836136/5-stocks-in-the-spotlight-from-wall-streets-most-accurate-analysts-last-week-4">5 Stocks In The Spotlight From Wall Street&#8217;s Most Accurate Analysts Last Week</a> </li>
</ul>
Photo via Shutterstock

ACLS

CSAN

LEGN

MTSR

NVTS

NWTN

PLUG

QUBT

RXRX

TERN

TSLA

Insmed, Tesla, Casey's General Stores And Other Big Stocks Moving Higher On Tuesday

–The Study Met Primary and All Secondary Efficacy Endpoints–
<ul>
<li>Statistically Significant 35% Placebo-Adjusted Reduction from Baseline in Pulmonary Vascular Resistance for the Primary Endpoint (p&lt;0.001)</li>
<li>35.5 Meter Placebo-Adjusted Improvement in Six-Minute Walk Distance for the Secondary Efficacy Endpoint (p=0.003)</li>
<li>60% Placebo-Adjusted Reduction from Baseline in NT-proBNP Concentrations for the Secondary Efficacy Endpoint (p&lt;0.001)</li>
<li>Results Were Assessed Approximately 24 Hours After Administration, Demonstrating Sustained Benefit Throughout the 24-Hour Dosing Period</li>
</ul>
–TPIP Was Well Tolerated in the Study, with 75% of Patients Titrating to the Highest Dose–
–Insmed to Immediately Engage with FDA to Inform Phase 3 Trial Design with Studies Expected to Begin Before End of 2025 for PH-ILD and in Early 2026 for PAH–
–Insmed to Host Investor Call at 8:00 AM ET on Tuesday, June 10, 2025–

Insmed's TPIP Demonstrates Statistically Significant 35% Reduction In Pulmonary Vascular Resistance And 35.5-Meter Improvement In Six-Minute Walk Distance In Phase 2 Study, Shows Sustained 24-Hour Benefits And Well Tolerated With 75% Patients Reaching Highest Dose

Insmed shares are trading higher after the company announced topline results from its randomized, double-blind, placebo-controlled Phase 2b study evaluating the efficacy and safety of treprostinil palmitil inhalation powder met its primary endpoint and all secondary efficacy endpoints.

Insmed Announces Topline Results From Phase 2b Study Of Treprostinil Palmitil Inhalation Powder (TPIP) As Once-Daily Therapy In Patients With Pulmonary Arterial Hypertension

Press Releases

New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis

Insmed Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028

Insmed To Present at the BofA Securities 2025 Health Care Conference

Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update

Brensocatib Shows Consistent Efficacy and Safety Across Three Prespecified Subgroups in New Data from Landmark ASPEN Study

Insmed To Present at the 2025 Goldman Sachs Annual Global Healthcare Conference

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension

Insmed Announces Proposed $650 Million Public Offering of Common Stock

Insmed Announces Pricing of $750 Million Public Offering of Common Stock

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

BioMarin Pharmaceutical

BioNTech

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Incyte

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeOne Medicines Ltd. - American Depositary Shares

BeOne Medicines

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Comments

Insmed

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL